Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Neuroscience ; 440: 146-159, 2020 08 01.
Article in English | MEDLINE | ID: mdl-32473275

ABSTRACT

The left inferior frontal gyrus and the bilateral ventral striatum are thought to be involved in motivation-mediated decision-making. Antipsychotics may influence this relationship, and atypical antipsychotics improve secondary negative symptoms in schizophrenia, such as loss of motivation, although the acute effects of pharmacological medication on motivation are not fully understood. In this single-blinded, randomized controlled trial, 49 healthy volunteers were randomized into three groups to receive a single dose of haloperidol, aripiprazole or placebo. Between 4.0 and 5.6 h later, participant's brain blood-oxygen-level dependent (BOLD) activity was recorded using functional magnetic resonance imaging (fMRI) while completing a perceptual decision-making fMRI task consisting of one neutral and one motivated condition. Response bias, reflecting the participant's willingness to say that the target stimulus is present, was calculated using signal detection theory. Concurrent with widespread changes in BOLD signal in the motivated vs. neutral condition, a less conservative, mathematically optimal response bias was observed in the motivated condition across the whole sample. Within-group differences in BOLD signal in the left inferior frontal gyrus and bilateral ventral striatum were observed between conditions in the aripiprazole and haloperidol groups, but not in the placebo group. No robust between-group differences in brain activity in the left inferior frontal gyrus or the bilateral ventral striatum were found. Overall, we found no robust evidence for an effect of either aripiprazole or haloperidol on motivationally mediated behavior. An interesting pattern of correlations possibly related to pharmacologically induced alterations in the dopamine system was observed, although findings remain inconclusive and must be replicated in larger samples.


Subject(s)
Antipsychotic Agents , Antipsychotic Agents/pharmacology , Aripiprazole , Brain/diagnostic imaging , Brain Mapping , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Motivation
2.
Neuroimage Clin ; 8: 290-7, 2015.
Article in English | MEDLINE | ID: mdl-26106553

ABSTRACT

BACKGROUND: Negative symptoms in schizophrenia have been associated with structural and functional changes in the prefrontal cortex. They often persist after treatment with antipsychotic medication which targets, in particular, the ventral striatum (VS). As schizophrenia has been suggested to arise from dysfunctional connectivity between neural networks, it is possible that residual aberrant striato-cortical connectivity in medicated patients plays a role in enduring negative symptomology. The present study examined the relationship between striato-cortical connectivity and negative symptoms in medicated schizophrenia patients. METHODS: We manipulated motivation in a perceptual decision-making task during functional magnetic resonance imaging. Comparing healthy controls (n = 21) and medicated patients with schizophrenia (n = 18) we investigated how motivation-mediated changes in VS activation affected functional connectivity with the frontal cortex, and how changes in connectivity strength from the neutral to motivated condition related to negative symptom severity. RESULTS: A pattern of aberrant striato-cortical connectivity was observed in the presence of intact VS, but altered left inferior frontal gyrus (IFG) motivation-mediated activation in patients. The more severe the patient's negative symptoms, the less the connectivity strength between the right VS and left IFG changed from the neutral to the motivated condition. Despite aberrant striato-cortical connectivity and altered recruitment of the left IFG among patients, both patients and healthy controls adopted a more liberal response strategy in the motivated compared to the neutral condition. CONCLUSIONS: The present findings suggest that there is a link between dysfunctional striato-cortical connectivity and negative symptom severity, and offer a possible explanation as to why negative symptoms persist after treatment with antipsychotics.


Subject(s)
Frontal Lobe/physiopathology , Reward , Schizophrenia/physiopathology , Ventral Striatum/physiopathology , Adult , Antipsychotic Agents/therapeutic use , Decision Making/physiology , Female , Humans , Magnetic Resonance Imaging , Male , Motivation/physiology , Neural Pathways/physiopathology , Perception/physiology , Schizophrenia/drug therapy , Severity of Illness Index , Young Adult
3.
Brain Behav ; 4(3): 398-407, 2014 May.
Article in English | MEDLINE | ID: mdl-24944869

ABSTRACT

INTRODUCTION: Changing the way we make decisions from one environment to another allows us to maintain optimal decision-making. One way decision-making may change is how biased one is toward one option or another. Identifying the regions of the brain that underlie the change in bias will allow for a better understanding of flexible decision-making. METHODS: An event-related, perceptual decision-making task where participants had to detect a picture of an animal amongst distractors was used during functional magnetic resonance imaging. Positive and negative financial motivation were used to affect a change in response bias, and changes in decision-making behavior were quantified using signal detection theory. RESULTS: Response bias became relatively more liberal during both positive and negative motivated trials compared to neutral trials. For both motivational conditions, the larger the liberal shift in bias, the greater the left inferior frontal gyrus (IFG) activity. There was no relationship between individuals' belief that they used a different strategy and their actual change in response bias. CONCLUSIONS: The present findings suggest that the left IFG plays a role in adjusting response bias across different decision environments. This suggests a potential role for the left IFG in flexible decision-making.


Subject(s)
Decision Making/physiology , Frontal Lobe/physiology , Motivation/physiology , Adult , Brain Mapping , Female , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Neuropsychological Tests , Young Adult
4.
PLoS One ; 8(6): e68494, 2013.
Article in English | MEDLINE | ID: mdl-23826392

ABSTRACT

Ability to anticipate aversive events is important for avoiding dangerous or unpleasant situations. The motivation to avoid an event is influenced by the incentive salience of an event-predicting cue. In an avoidance fMRI task we used tone intensities to manipulate salience in order to study the involvement of the orbitofrontal cortex in processing of incentive salience. In the task, cues predicting either aversive or neutral avoidable tones were presented. Ventral striatum, amygdala and anterior insula activations were significantly stronger during presentation of cues for aversive than neutral tones. A psychophysiological interaction analysis showed stronger connectivity between the ventral striatum and the orbitofrontal cortex during aversive than neutral conditions. The present study shows an interaction between the ventral striatum, a structure previously linked to negative incentive salience, and the orbitofrontal cortex supporting a role for this region in processing salience. In addition, this study replicates previous findings suggesting that the task is robust.


Subject(s)
Anticipation, Psychological , Basal Ganglia/physiology , Cerebral Cortex/physiology , Magnetic Resonance Imaging , Neural Pathways/physiology , Task Performance and Analysis , Adult , Avoidance Learning , Behavior , Cluster Analysis , Cues , Female , Humans , Image Processing, Computer-Assisted , Male , Oxygen/blood
5.
Neuroimage ; 62(1): 95-101, 2012 Aug 01.
Article in English | MEDLINE | ID: mdl-22546319

ABSTRACT

While the amygdala historically has been implicated in emotional stimuli processing, recent data suggest a general role in parceling out the relevance of stimuli, regardless of their emotional properties. Using functional magnetic resonance imaging, we tested the relevance hypothesis by investigating human amygdala responses to emotionally neutral stimuli while manipulating their relevance. The task was operationalized as highly relevant if a subsequent opportunity to respond for a reward depended on response accuracy of the task, and less relevant if the reward opportunity was independent of task performance. A region of interest analysis revealed bilateral amygdala activations in response to the high relevance condition compared to the low relevance condition. An exploratory whole-brain analysis yielded robust similar results in bilateral ventral striatum. A subsequent functional connectivity analysis demonstrated increased connectivity between amygdala and ventral striatum for the highly relevant stimuli compared to the less relevant stimuli. These findings suggest that the amygdala's processing profile goes beyond detection of emotions per se, and directly support the proposed role in relevance detection. In addition, the findings suggest a close relationship between amygdala and ventral striatal activity when processing relevant stimuli. Thus, the results may indicate that human amygdala modulates ventral striatum activity and subsequent behaviors beyond that observed for emotional cues, to encompass a broader range of relevant stimuli.


Subject(s)
Amygdala/physiology , Corpus Striatum/physiology , Emotions/physiology , Evoked Potentials/physiology , Motivation/physiology , Reward , Task Performance and Analysis , Adult , Brain Mapping , Female , Humans , Magnetic Resonance Imaging , Male , Nerve Net/physiology , Neural Pathways/physiology
6.
Int J Neuropsychopharmacol ; 14(9): 1165-78, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21087552

ABSTRACT

While dopamine D2 receptor partial agonists (PAs) have been long considered for treating schizophrenia, only one, aripiprazole, is clinically available for therapeutic use. This raises critically important questions as to what is unique about aripiprazole and to what extent animal models can predict therapeutic success. A number of PAs whose clinical fate is known: aripiprazole, preclamol, terguride, OPC-4392 and bifeprunox were compared to haloperidol (a reference antipsychotic) in several convergent preclinical animal models; i.e. amphetamine-induced locomotion (AIL) and conditioned avoidance response (CAR), predictive of antipsychotic effects; unilateral nigrostriatal lesioned rats, a model of hypo-dopaminergia; striatal Fos induction, a molecular marker for antipsychotic activity; and side-effects common to this class of drugs: catalepsy (motor side-effects) and prolactaemia. The results were compared across drugs with reference to their measured striatal D2 receptor occupancy. All the PAs occupied striatal D2 receptors in a dose dependent manner, inhibited AIL and CAR, and lacked motor side-effects or prolactinaemia despite D2 receptor occupancy exceeding 80%. At comparative doses, aripiprazole distinguished itself from the other PAs by causing the least rotation in the hypo-dopaminergic model (indicating the least intrinsic activity) and showed the highest Fos expression in the nucleus accumbens (indicating functional D2 antagonism). Although a number of PAs are active in antipsychotic animal models, not all of them succeed. Given that only aripiprazole is clinically available, it can be inferred that low functional intrinsic activity coupled with sufficient functional antagonism as reflected in the animal models may be a marker of success.


Subject(s)
Antipsychotic Agents/therapeutic use , Dopamine Agonists/therapeutic use , Receptors, Dopamine D2/agonists , Schizophrenia/drug therapy , Animals , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Antipsychotic Agents/metabolism , Aripiprazole , Avoidance Learning/drug effects , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Corpus Striatum/pathology , Dopamine Agonists/administration & dosage , Dopamine Agonists/adverse effects , Dopamine Agonists/metabolism , Dopamine Antagonists/administration & dosage , Dopamine Antagonists/adverse effects , Dopamine Antagonists/metabolism , Dopamine Antagonists/therapeutic use , Dopamine D2 Receptor Antagonists , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Immunohistochemistry , Locomotion/drug effects , Male , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Neurons/metabolism , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Nucleus Accumbens/pathology , Piperazines/administration & dosage , Piperazines/adverse effects , Piperazines/metabolism , Piperazines/therapeutic use , Proto-Oncogene Proteins c-fos/metabolism , Quinolones/administration & dosage , Quinolones/adverse effects , Quinolones/metabolism , Quinolones/therapeutic use , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D2/metabolism
7.
Schizophr Res ; 105(1-3): 224-35, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18710798

ABSTRACT

INTRODUCTION: Amisulpride's high and selective affinity for dopamine D2/3 (Ki 1.3/2.4 nM) receptors, lack of affinity for serotonin receptors, and its unusually high therapeutic doses (400-800 mg/day) makes it unique among atypical antipsychotics and prompted us to compare its actions with other antipsychotics in animal models. METHODS: Amisulpride's effects on amphetamine and phencyclidine induced locomotor activity (AIL/PIL), conditioned avoidance response, catalepsy (CAT), subcortical Fos expression, and plasma prolactin was correlated to its time-course striatal D2/3 and prefrontal 5-HT2 receptor occupancy (D(2/3)/5-HT2RO); in comparison to haloperidol, clozapine, and risperidone. RESULTS: Unlike the atypicals clozapine and risperidone, amisulpride lacked 5-HT2RO and showed a 'delayed' pattern of D2/3RO: 43, 60 and 88% after 1, 2 and 6 h (100 mg/kg), respectively, despite a quick onset (1 h) and decline (6 h) of prolactin elevation. While haloperidol and risperidone were effective at D2RO>60%, clozapine at D2/3RO<50%, amisulpride was effective only when its D2RO exceeded 60% with a delayed latency and lasted longer than other antipsychotics. CAT was observed for haloperidol and risperidone when D2RO exceeded 80%, while in the case of amisulpride, CAT was not observed even when doses exceeded 90% D2/3RO. Amisulpride also displayed functional limbic selectivity in Fos expression like the other atypicals. CONCLUSIONS: Amisulpride's "delayed" functional profile on acute administration and the need for high doses is most likely due to its poor blood-brain-barrier penetration; however, it is distinct from other atypicals in showing low motor side-effects, activity against phencyclidine, and a mesolimbic preference, despite no action on serotonin receptors.


Subject(s)
Antipsychotic Agents/pharmacology , Brain/drug effects , Receptors, Dopamine/drug effects , Receptors, Serotonin/drug effects , Sulpiride/analogs & derivatives , Amisulpride , Amphetamine/antagonists & inhibitors , Amphetamine/pharmacology , Animals , Antipsychotic Agents/metabolism , Basal Ganglia/drug effects , Basal Ganglia/metabolism , Behavior, Animal/drug effects , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/metabolism , Brain/metabolism , Clozapine/metabolism , Clozapine/pharmacology , Conditioning, Psychological/drug effects , Haloperidol/metabolism , Haloperidol/pharmacology , Male , Models, Animal , Motor Activity/drug effects , Phencyclidine/antagonists & inhibitors , Phencyclidine/pharmacology , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Prolactin/blood , Prolactin/drug effects , Rats , Rats, Sprague-Dawley , Receptors, Dopamine/metabolism , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D3/drug effects , Receptors, Dopamine D3/metabolism , Receptors, Serotonin/metabolism , Risperidone/metabolism , Risperidone/pharmacology , Sulpiride/metabolism , Sulpiride/pharmacology
8.
Psychopharmacology (Berl) ; 199(2): 275-89, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18521575

ABSTRACT

RATIONALE: l-Stepholidine, a dopamine D(2) antagonist with D(1) agonist activity, should in theory control psychosis and treat cognitive symptoms by enhancing cortical dopamine transmission. Though several articles describe its impact on the dopamine system, it has not been systematically evaluated and compared to available antipsychotics. MATERIALS AND METHODS: We examined its in vitro interaction with dopamine D(2) and D(1) receptors and compared its in vivo pharmacokinetic profile to haloperidol (typical) and clozapine (atypical) in animal models predictive of antipsychotic activity. RESULTS: In vitro, l-stepholidine showed significant activity on dopamine receptors, and in vivo, l-stepholidine demonstrated a dose-dependent striatal receptor occupancy (RO) at D(1) and D(2) receptors (D(1) 9-77%, 0.3-30 mg/kg; D(2) 44-94%, 1-30 mg/kg), though it showed a rather rapid decline of D(2) occupancy related to its quick elimination. In tests of antipsychotic efficacy, it was effective in reducing amphetamine- and phencyclidine-induced locomotion as well as conditioned avoidance response, whereas catalepsy and prolactin elevation, the main side effects, appeared only at high D(2)RO (>80%). This preferential therapeutic profile was supported by a preferential immediate early gene (Fos) induction in the nucleus accumbens over dorsolateral striatum. We confirmed its D(1) agonism in vitro, and then using D(2) receptor, knockout mice showed that l-stepholidine shows D(1) agonism in the therapeutic dose range. CONCLUSIONS: Thus, l-stepholidine shows efficacy like an "atypical" antipsychotic in traditional animal models predictive of antipsychotic activity and shows in vitro and in vivo D(1) agonism, and, if its rapid elimination does not limit its actions, it could provide a unique therapeutic approach to schizophrenia.


Subject(s)
Antipsychotic Agents/pharmacology , Berberine/analogs & derivatives , Dopamine D2 Receptor Antagonists , Receptors, Dopamine D1/agonists , Amphetamine/pharmacology , Animals , Antipsychotic Agents/pharmacokinetics , Avoidance Learning/drug effects , Berberine/pharmacokinetics , Berberine/pharmacology , Brain Chemistry/drug effects , Catalepsy/chemically induced , Catalepsy/psychology , Central Nervous System Stimulants/pharmacology , Dose-Response Relationship, Drug , Excitatory Amino Acid Antagonists/pharmacology , Genes, fos/drug effects , Hallucinogens/pharmacology , Immunohistochemistry , Male , Mice , Mice, Knockout , Motor Activity/drug effects , Phencyclidine/pharmacology , Prolactin/blood , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D1/genetics , Receptors, Dopamine D2/genetics
9.
Biol Psychiatry ; 64(2): 145-52, 2008 Jul 15.
Article in English | MEDLINE | ID: mdl-18295747

ABSTRACT

BACKGROUND: Most studies on the effects of antipsychotics focus on achieving threshold levels of the drug. The speed and frequency with which drug concentrations reach threshold levels and rise and fall within the day are generally ignored. Based on prior data, we predicted that variations in the within-day kinetics of antipsychotic drug delivery would produce different outcomes, even if we held achieved dose, route, and total duration of treatment constant. METHODS: We compared the effects of within-day continuous (via minipump) versus transient (via subcutaneous injection) haloperidol treatment (n = 4-9/condition/experiment) at doses that yield equivalent peak levels of striatal D2 receptor occupancy (approximately 74%). RESULTS: Over time, transient haloperidol gained efficacy, while continuous haloperidol lost efficacy in two animal models of antipsychotic-like effects (the suppression of amphetamine-induced locomotion and conditioned avoidance responding). This was related to the fact that continuous treatment led to a greater increase in striatal D2 receptor numbers--particularly D2 receptors in a high-affinity state for dopamine--relative to transient treatment and produced behavioral dopamine supersensitivity (as indicated by an enhanced locomotor response to amphetamine following antipsychotic treatment cessation). Treatment kinetics also influenced the postsynaptic response to haloperidol. Transient treatment increased striatal c-fos messenger RNA (mRNA) expression, while continuous treatment did not. CONCLUSIONS: Relative to continuous antipsychotic exposure, within-day transient exposure is more efficacious behaviorally and is associated with a distinct molecular and gene expression profile. Thus, differences in the within-day kinetics of antipsychotic treatment can have different efficacy, and the potential clinical implications of this should be explored further.


Subject(s)
Antipsychotic Agents/administration & dosage , Haloperidol/administration & dosage , Animals , Antipsychotic Agents/pharmacokinetics , Avoidance Learning/drug effects , Biological Availability , Conditioning, Classical/drug effects , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Dextroamphetamine/pharmacology , Drug Administration Schedule , Gene Expression/drug effects , Haloperidol/pharmacokinetics , Infusion Pumps , Injections, Subcutaneous , Kinetics , Male , Metabolic Clearance Rate/physiology , Motor Activity/drug effects , Proto-Oncogene Proteins c-fos/genetics , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/metabolism , Treatment Outcome
10.
Neuropsychopharmacology ; 32(7): 1540-9, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17164815

ABSTRACT

There is growing interest in N-desmethylclozapine (NDMC), the major metabolite of clozapine, as a unique antipsychotic because it acts in vitro as a 5-HT(2) antagonist and as a partial agonist to dopamine D(2) and muscarinic receptors. To explore this, we compared NDMC to a typical (haloperidol), atypical (clozapine), and partial-agonist atypical (aripiprazole) antipsychotic in preclinical models. The comparison was carried out using: brain D(2) and 5-HT(2) receptor occupancy; animal models predictive of antipsychotic efficacy (amphetamine-induced hyperlocomotion (AIL) and conditioned avoidance response (CAR) models); measures predictive of side effects (catalepsy and prolactin elevation); and molecular markers predictive of antipsychotic action (striatal Fos induction). NDMC (10-60 mg/kg/s.c.) showed high 5-HT(2) (64-79%), but minimal D(2) occupancy (<15% at 60 mg/kg) 1 h after administration. In contrast to other antipsychotics, NDMC was not very effective in reducing AIL or CAR and showed minimal induction of Fos in the nucleus accumbens. However, like atypical antipsychotics, it showed no catalepsy, prolactin elevation, and minimal Fos in the dorsolateral striatum. It seems unlikely that NDMC would show efficacy as a stand-alone antipsychotic, however, its freedom from catalepsy and prolactin elevation, and its unique pharmacological profile (muscarinic agonism) may make it feasible to use this drug as an adjunctive treatment to existing antipsychotic regimens.


Subject(s)
Antipsychotic Agents/pharmacology , Brain Chemistry/drug effects , Brain/drug effects , Clozapine/analogs & derivatives , Psychotic Disorders/drug therapy , Animals , Aripiprazole , Avoidance Learning/drug effects , Avoidance Learning/physiology , Biomarkers/blood , Brain/metabolism , Brain/physiopathology , Brain Chemistry/physiology , Catalepsy/chemically induced , Clozapine/pharmacology , Dopamine Agonists/pharmacology , Drug Evaluation, Preclinical , Haloperidol/pharmacology , Male , Piperazines/pharmacology , Prolactin/blood , Proto-Oncogene Proteins c-fos/metabolism , Psychotic Disorders/metabolism , Psychotic Disorders/physiopathology , Quinolones/pharmacology , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D2/metabolism , Receptors, Serotonin, 5-HT2/drug effects , Receptors, Serotonin, 5-HT2/metabolism , Serotonin Antagonists/pharmacology , Treatment Outcome
11.
J Pharmacol Exp Ther ; 318(2): 810-8, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16648369

ABSTRACT

"Dopamine stabilizers" are a new class of compounds that have the ability to reverse both hypo- as well as hyperdopaminergia in vivo. This class, exemplified by the phenylpiperidines (S)-(-)-3-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl)-piperidine [ACR16] although lacking high in vitro binding affinity for dopamine D2 receptor [(-)-OSU6162, Ki = 447 nM; ACR16, Ki > 1 microM], shows functional actions, suggestive of their interaction. Hence, we evaluated in vivo D2 occupancy of these agents in rats and correlated it to observed effects in a series of behavioral, neurochemical, and endocrine models relevant to the dopamine system and antipsychotic effect. Both (-)-OSU6162 and ACR16 showed robust dose-dependent striatal D2 occupancy with ED50 values of 5.27 and 18.99 mg/kg s.c., respectively, and functional assays showed no partial agonism. Over an occupancy range of 37 to 87% (3-60 mg/kg) for (-)-OSU6162 and 35 to 74% (10-60 mg/kg) for ACR16, we observed both inhibitory (amphetamine-induced locomotor activity) and stimulatory effects (in habituated rats). Haloperidol, over a similar occupancy range (33-78%), potently inhibited psychostimulant activity and induced catalepsy, but it failed to activate habituated animals. In the conditioned avoidance response assay, ACR16 was clearly more efficacious than (-)-OSU6162. In addition, both these compounds demonstrated significant preferential Fos induction in the nucleus accumbens compared with the dorsolateral striatum, a strong predictor of atypical antipsychotic efficacy. The results suggest that dopamine stabilizers exhibit locomotor stabilizing as well as antipsychotic-like effects, with low motor side effect liability, in a dose range that corresponds to high D2 in vivo occupancy.


Subject(s)
Antipsychotic Agents , Dopamine Agents/pharmacology , Dyskinesia, Drug-Induced/psychology , Piperidines/pharmacology , Receptors, Dopamine D2/metabolism , Animals , Avoidance Learning/drug effects , Binding, Competitive/drug effects , Dihydroxyphenylalanine/metabolism , Dopamine Agents/metabolism , Dopamine Agents/toxicity , Dopamine Antagonists/metabolism , Haloperidol/metabolism , Immunohistochemistry , Male , Motor Activity/drug effects , Neostriatum/drug effects , Neostriatum/metabolism , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Piperidines/metabolism , Piperidines/toxicity , Prolactin/blood , Proto-Oncogene Proteins c-fos/biosynthesis , Rats , Rats, Sprague-Dawley , Reserpine/metabolism
12.
Neuropsychopharmacology ; 31(9): 1854-63, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16319908

ABSTRACT

The novel antipsychotic aripiprazole requires high (>90%) striatal D2 receptor occupancy (D2RO) to be clinically active, but despite its high D2RO it does not show extrapyramidal symptoms. While most antipsychotics are active at nearly 65% D2RO, they show motor side effects when D2RO exceeds 80%. We investigated this discrepancy between D2RO, 5HT2 receptor occupancy (5-HT2RO) and in vivo functional activity of aripiprazole in comparison to haloperidol (typical) and risperidone (atypical) in animal models. All three drugs showed dose-dependent D2RO. While risperidone clearly showed higher 5-HT2RO than D2RO, aripiprazole and haloperidol showed higher D2RO than 5-HT2RO at all doses. Haloperidol and risperidone induced catalepsy at doses producing >80% D2RO, while aripiprazole despite higher D2RO (>90%) induced no catalepsy. Haloperidol and risperidone's ED50 values for inhibition of conditioned avoidance response (CAR) and amphetamine-induced locomotor activity (AIL) corresponded to approximately 60% D2RO. In contrast, aripiprazole showed a significant dissociation; while it blocked AIL at similar D2RO, a 23-fold higher dose (86% D2RO) was required to inhibit CAR. FOS expression in shell region of the nucleus accumbens was significant for all drugs at D2ROs that were effective in CAR. However, in the core region of the nucleus accumbens and dorsolateral striatum, aripiprazole differed from the others in that despite high D2RO it induced low FOS. Haloperidol and risperidone showed dose/occupancy-dependent prolactin elevations, while aripiprazole did not. Across models, haloperidol and risperidone show similar occupancy-functional antagonism of the D2 system, while aripiprazole shows a clear dissociation. Partial agonism of aripiprazole offers a good explanation for this dissociation and provides a framework for understanding occupancy-functional relationships of partial D2 agonist antipsychotics.


Subject(s)
Antipsychotic Agents/pharmacology , Dopamine D2 Receptor Antagonists , Piperazines/pharmacology , Quinolones/pharmacology , Receptors, Dopamine D2/metabolism , Animals , Aripiprazole , Avoidance Learning/drug effects , Catalepsy/chemically induced , Catalepsy/psychology , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Immunohistochemistry , Male , Motor Activity/drug effects , Oncogene Proteins v-fos/biosynthesis , Prolactin/blood , Rats , Rats, Sprague-Dawley , Risperidone/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...